Meeshanthini Dogan
Vorstandsvorsitzender bei CARDIO DIAGNOSTICS HOLDINGS, INC.
Vermögen: 1 Mio $ am 31.05.2024
Aktive Positionen von Meeshanthini Dogan
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CARDIO DIAGNOSTICS HOLDINGS, INC. | Direktor/Vorstandsmitglied | 25.10.2022 | - |
| Vorstandsvorsitzender | 25.10.2022 | - | |
Cardio Diagnostics, Inc.
 Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Direktor/Vorstandsmitglied | 01.05.2017 | - |
| Vorstandsvorsitzender | 01.05.2017 | - | |
| Gründer | 01.05.2017 | - |
Karriereverlauf von Meeshanthini Dogan
Ausbildung von Meeshanthini Dogan
| University of Iowa | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 3 |
| 2 |
Operativ
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sektoral
| Consumer Services | 2 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cardio Diagnostics, Inc.
Cardio Diagnostics, Inc. Medical/Nursing ServicesHealth Services Part of Cardio Diagnostics Holdings, Inc., Cardio Diagnostics, Inc. is a biotechnology company based in Chicago, IL. The company is focused on making cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's flagship solution, the Cardio Diagnostics Epi+Gen CHD™ test, helps clinicians better assess each patient's unique risk profile for disease. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. Cardio Diagnostics was founded in 2017 by Meeshanthini Dogan and Robert Philibert, with Meeshanthini Dogan serving as CEO since then. Cardio Diagnostics was acquired by Mana Capital Acquisition Corp. on October 25, 2022 for $61.51 million. | Health Services |
| Cardio Diagnostics Holdings, Inc. |
- Börse
- Insiders
- Meeshanthini Dogan
- Erfahrung